Patient Access Scheme
Health
John Leech (Manchester, Withington, Liberal Democrat)
To ask the Secretary of State for Health what (a) pharmacological treatments and (b) associated indications for a patient access scheme have been recommended by the National Institute for Health and Clinical Excellence since it was established.
Simon Burns (Minister of State (Health), Health; Chelmsford, Conservative)
The treatments recommended by the National Institute for Health and Clinical Excellence where a patient access scheme was considered as part of the relevant technology appraisal are listed in the following table. Further information is available on the Institute's website at:
www.nice.org.uk/aboutnice/howwework/paslu/patientaccessschemesliaisonunit.jsp
| Technology appraisal (TA) number | Treatment | Indication |
| TA129 | Bortezomib (Velcade) | Multiple myeloma |
| TA155 | Ranibizumab (Lucentis) | Macular degeneration (Acute wet AMD) |
| TA162 | Erlotinib (Tarceva) | Non small cell lung cancer |
| TA169 | Sunitinib (Sutent) | Renal cell carcinoma |
| TA171 | Lenalidomide (Revlimid) | Multiple myeloma |
| TA176 | Cetuximab (Erbitux) | Metastatic colorectal cancer (first line) |
| TA179 | Sunitinib (Sutent) | Gastrointestinal stromal tumour |
| TA180 | Ustekinumab (Stelera) | Moderate to severe psoriasis |
| TA185 | Trabectedin (Yondelis) | Advanced soft tissue sarcoma |
| TA186 | Certolizumab pegol (Cimzia) | Rheumatoid arthritis |
| TA192 | Gefitinib (Iressa) | Non small cell lung cancer |
| TA215 | Pazopanib (Votrient) | Advanced renal cell carcinoma |
| TA218 | Azacitidine (Vidaza) | Myelodysplastic syndromes, chronic myelomonocytic leukaemia and acute myeloid leukaemia |
| TA220 | Golimumab (Simponi) | Psoriatic arthritis |
| TA221 | Romiplostim (Nplate) | Chronic idiopathic (immune) thrombocytopenic purpura |
| TA225 | Golimumab (Simponi) | Rheumatoid arthritis |
| TA233 | Golimumab (Simponi) | Ankylosing spondylitis |
| TA235 | Mifamurtide (Mepact) | High grade resectable non-metastic osteosarcoma |
| TA238 | Tocilizumab (RoActemra) | Systemic juvenile idiopathic arthritis |
| TA241 | Nicotinic (Taiga) | Imagine-resistant chronic myeloid leukaemia |